Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

• Main Authors: Elizabeth K. Lee (Author), Zhenying Tan-Wasielewski (Author), Ursula A. Matulonis (Author), Michael J. Birrer (Author), Alexi A. Wright (Author), Neil Horowitz (Author), Panagiotis A. Konstantinopoulos (Author), Jennifer Curtis (Author), Joyce F. Liu (Author)
• Format: Book
• Published: Elsevier, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...